Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
My Portfolio
Regen Biopharma Inc
(OP:
RGBP
)
0.0593
USD
UNCHANGED
Streaming Delayed Price
Updated: 4:02 PM EDT, Apr 12, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.0593
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0593
Today's Range
0.0593 - 0.0593
52wk Range
0.0001 - 0.0819
Shares Outstanding
151,327,211
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Regen BioPharma, Inc. Discovers Fundamental Role of NR2F6 in Production of Malignant Blood Vessels
November 01, 2019
Laboratory Data and Patent Filing Supports Possible Treatments for Wet Macular Degeneration and Cancer
From
PR Newswire
Regen BioPharma Successfully Treats Rheumatoid Arthritis Using Cannabidiol (CBD) Based Immune Modulatory Treatments
October 03, 2019
Company Develops Novel T Regulatory Cell Activating Approach Potentially Useful for Diverse Autoimmune and Inflammatory Diseases
From
PR Newswire
Performance
YTD
+7312.50%
+7312.50%
1 Month
+3853.33%
+3853.33%
3 Month
+7312.50%
+7312.50%
6 Month
+11760.00%
+11760.00%
1 Year
+59200.00%
+59200.00%
More News
Read More
Regen BioPharma Discovers Potential New Way to Improve Outcomes from Cancer Surgery Using Combination of Cannabidiol and NR2F6 Inhibition
August 15, 2019
From
PR Newswire
Regen BioPharma Inc. Files Immuno-Oncology Patent Application on Synergy of Cannabidiol With NR2F6 Modulation
August 07, 2019
From
PR Newswire
Regen BioPharma, Inc. Responds to Fake News Release
May 08, 2019
From
PR Newswire
Regen BioPharma, Inc. Examines Combining Cannabidiol (CBD) With Its Lead NR2F6 Agonist To Treat for Inflammatory Bowel Disease
January 08, 2019
From
PR Newswire
Regen BioPharma, Inc. Reports Additional New NR2F6 Small Molecule Inhibitors
November 13, 2018
From
PR Newswire
Increasing Number of Cancer Cases to Fuel the Global Cancer Immunotherapy Market Growth
October 05, 2018
From
PR Newswire
Regen BioPharma, Inc. Determines Its Lead NR2F6 Agonist Ready for Inflammatory Bowel Disease Animal Studies
October 04, 2018
From
PR Newswire
Cancer Immunotherapy Treatment Market on the Rise as R&D Increases
September 21, 2018
From
PR Newswire
Regen BioPharma, Inc. Reports Activation of Immune Cells by Its NR2F6 Small Molecule Inhibitors
September 21, 2018
From
PR Newswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.